• Dr. Lee was born in Seoul, South Korea where he attended college. He received his medical degree and PhD from Korea University College of Medicine. In Korea, he was an intern, resident in medicine, and clinical fellow in gastroenterology at Korea University Hospital. After 40-month service of an Army Surgeon from South Korea Army, he was a faculty member of Gastroenterology at Department of Internal Medicine, Dongguk University College of Medicine, Gyeongju, South Korea. He move out to the US when he accepted a Visiting Research Assistant Professor at University of Illinois at Chicago Department of Chemistry, Chicago, IL. He was a post-doctoral research associate and a Research Assistant Professor at Northwestern University Feinberg School of Medicine, Chicago, IL. After Northwestern for 6 year, he completed pathology residency at University of Illinois at Chicago and completed a gastrointestinal pathology fellowship at Emory University, Atlanta, GA. Prior to coming to UAB in 2018, he was a faculty member at University of Ottawa, Department of Pathology and Laboratory Medicine, Ottawa, ON, Canada.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2022 MiR-214-3p targets Ras-related protein 14 (RAB14) to inhibit cellular migration and invasion in esophageal Cancer cellsBMC Cancer.  22. 2022
    2022 Hedgehog blockade remodels the gut microbiota and the intestinal effector CD8+ T cells in a mouse model of mammary carcinomaLaboratory Investigation.  102:1236-1244. 2022
    2022 Role of Hepatitis C Infection in Acute Liver Injury/Acute Liver Failure in North America.Digestive Diseases and Sciences.  1-8. 2022
    2022 Pharmacokinetics and Safety Studies in Rodent Models Support Development of EPICERTIN as a Novel Topical Wound-Healing Biologic for Ulcerative ColitisJournal of Pharmacology and Experimental Therapeutics.  380:162-170. 2022
    2022 Gastrointestinal Manifestations of COVID-19 Infection: Clinicopathologic Findings in Intestinal Resections Performed at Single InstitutionFrontiers in Medicine.  9. 2022
    2022 Vedolizumab Therapy in Refractory Enteropathy Associated With CVID.ACG Case Reports Journal.  9:e00721. 2022
    2021 Atypical spindle cell/pleomorphic lipomatous tumor of the stomach: A case reportHuman Pathology: Case Reports.  25. 2021
    2021 ICOS ligand and IL-10 synergize to promote host–microbiota mutualism 2021
    2020 Monomorphic Epitheliotropic Intestinal T-cell Lymphoma: A Study of Four Cases and Review of LiteratureAnnals of Clinical and Laboratory Science.  50:806-812. 2020
    2019 Vaginal Vault Traumatic Neuromas.Journal of Minimally Invasive Gynecology.  26. 2019
    2018 809 - Epithelial-Specific P85α KO Enhances Crypt Resilience to Radiation InjuryGastroenterology.  154:s-166. 2018
    2017 Epithelial TNF receptor signaling promotes mucosal repair in inflammatory bowel diseaseJournal of Immunology.  199:1886-1897. 2017
    2017 Expression of Lewis-a glycans on polymorphonuclear leukocytes augments function by increasing transmigration.Journal of Leukocyte Biology.  102:753-762. 2017
    2017 Pancreatic Neuroendocrine Tumors Complicated by Sinistral Portal Hypertension: Insights into Pathogenesis.Journal of Pancreatic Cancer.  3:71-77. 2017
    2017 Perianal Pagetoid Intraepithelial Carcinoma.Case Reports in Gastroenterology.  11:109-113. 2017
    2014 Su1992 TNF Mediates β-Catenin Activation in Intestinal Stem Cells During ColitisGastroenterology.  146:s-516. 2014
    2013 Fluorescence endoscopy of cathepsin activity discriminates dysplasia from colitis.Inflammatory Bowel Diseases.  19:1339-1345. 2013
    2013 PI3K/AKT signaling is essential for communication between tissue-infiltrating mast cells, macrophages, and epithelial cells in colitis-induced cancerClinical Cancer Research.  19:2342-2354. 2013
    2012 177 The Roles of TNFR Signaling and NOX1 in Epithelial ß-Catenin Activation During ColitisGastroenterology.  142:s-44. 2012
    2010 Mesalamine inhibits epithelial beta-catenin activation in chronic ulcerative colitis.Gastroenterology.  138:595-605.e3. 2010
    2010 Epithelial NF-κB enhances transmucosal fluid movement by altering tight junction protein composition after T cell activationAmerican Journal of Pathology.  176:158-167. 2010
    2010 Phosphoinositide 3-kinase signaling mediates β-catenin activation in intestinal epithelial stem and progenitor cells in colitisGastroenterology.  139. 2010
    2009 DNA-driven nutritional therapy of inflammatory bowel disease.Nutrition.  25:885-891. 2009
    2009 242 Melatonin Prevents Colitis-Induced Dysplasia Through Inhibition of PI3K-Mediated β-Catenin SignalingGastroenterology.  136:a-47. 2009
    2009 S1653 IL- 6 Contributes to Epithelial Stem Cell Activation During Chronic ColitisGastroenterology.  136:a-243. 2009
    2009 W1602 TNF Mediated iNOS Induces p53-Dependent Crypt Cell Apoptosis in ColitisGastroenterology.  136:a-700. 2009
    2008 Therapeutic benefit of pentostatin in severe IL-10-/- colitis.Inflammatory Bowel Diseases.  14:880-887. 2008
    2008 T1221 Deletion of P-Selectin Glycoprotein1 Accelerates the Onset and Worsens IL-10-/- ColitisGastroenterology.  134:a-509-a-510. 2008
    2005 Anti-interferon-inducible chemokine, CXCL10, reduces colitis by impairing T helper-1 induction and recruitment in mice.Inflammatory Bowel Diseases.  11:799-805. 2005
    2003 A large malignant insulinoma: case report with endosonographic, immunohistochemical and ultrastructural features.The Korean Journal of Internal Medicine.  18:45-49. 2003
    2002 A clinical study of patients with acute liver injury caused by herbal medication in Gyeongju area.The Korean Journal of Internal Medicine.  63:141-151. 2002
    2002 Expression of p27Kip1 in gastric cancers and precancerous lesionsThe Korean Journal of Internal Medicine.  63:141-141. 2002
    2001 Effects of taurine on cerulein-induced acute pancreatitis in the rat.Pharmacology.  63:1-7. 2001
    1999 Metastasis-induced acute pancreatitis in a patient with small cell carcinoma of the lung.Journal of Korean Medical Science.  14:107-109. 1999


    Year Title Altmetric
    2014 Intestinal stem cells in physiologic regeneration and disease 2014

    Research Overview

  • 1) Chronic Inflammation, Molecular Pathways involving Intestinal Stem/Progenitor Cell Activation
    and Chemoprevention in Inflammatory Bowel Disease-Associated Colorectal Cancer.
    Inflammatory bowel disease (IBD) is a longstanding inflammatory condition in the intestine and the risk for developing colorectal cancer is increased compared to the general population. Appropriately, then, patients, physician, and researchers are quite concerned about how to recognize (early detection) and prevent this fatal complication. Wnt/-catenin pathway is essential for intestinal homeostasis, including controlling intestinal stem cells (ISCs). In sporadic colorectal cancer, mutations (such as APC) that lead to activation of Wnt/-catenin pathway occur in most of cases. However, activation of Wnt/-catenin pathway by chronic inflammation such as IBD remains to be elucidated. My colleague and I proposed that chronic inflammation-mediated activation of PI3K/Akt signaling cooperated with Wnt to increase nuclear -catenin. We also demonstrated that Pi3k/Akt phosphorylated -catenin at Serine 552. Whereas N-terminal phosphorylation of -catenin triggers destruction, PI3k/Akt phosphorylation of -catenin near C-terminal causes nuclear translocation and increased transcription of target genes (cMyc, cyclinD1). PI3K inhibition in mice colitis-associated colon cancer model reduced epithelial Akt and -catenin activation, reduced stem/progenitor cell expansion, and reduced dysplasia. In conclusion, PI3K/Akt-mediated -catenin signaling is required for intestinal stem/progenitor activation during transformation from chronic colitis to colitis-associated colorectal cancer. Blocking PI3K pathway emerged as a biomarker of carcinogenesis and chemoprevention target in IBD-associated colorectal cancer from our results. A variety of pharmaceuticals which inhibit PI3K, Akt or the downstream target mTOR have been undergoing clinical trials in a variety of malignancies. Therefore we may soon see a move to combined endoscopic and biomarker- based surveillance that are able to identify those patient at high risk and even start chemopreventive drugs.

    2) TNF medicates -catenin Activation in Intestinal Stem Cells in Inflammatory Bowel Disease.
    TNF (tumor necrosis factor) is a cytokine, i.e., a cellular regulator that acts by triggering a specific cell-surface receptor (TNFR1 and TNFR2). TNF blockade by anti-TNF antibody in inflammatory bowel disease indicates that TNF is a central mediator of inflammation. TNF also alters cell proliferation and death. We hypothesized that TNF directly mediated ISC/progenitor responses in IBD through activation of Wnt/-catenin pathway. Data from human Crohn' show that anti-TNF reduces epithelial β-catenin and proliferation independent of inflammation. Data in intact and bone marrow chimera (BMC) Tnf-/- and Tnfr1/2-/- mice indicate that BM-derived TNF increases epithelial BrdU incorporation and β-catenin in crypt base-columnar (CBC) and transit amplifying cells and BAT-gal in CBC. TNF treatment of enteroid cultures increases ISC transcriptome including CD44 and Ascle2 mRNA and Ascl2 targets, Ets2 and TNFRSF19. TNF blockade abrogates colitis-induced dysplasia and limits epithelial BrdU and β-catenin levels in IL10-/- mice. The results are consistent with the model that TNF activates epithelial Wnt/β-catenin signaling and proliferation in IBD. These findings suggest that early anti-TNF therapy may attenuate the risk for dysplasia by reducing early stem cell activation during periods of severe mucosal inflammation.

    3) Early Detection of Dysplasia in Inflammatory Bowel Disease.
    Due to high risk for developing colorectal cancer in IBD, patient with long-standing IBD undergo surveillance colonoscopy. Surveillance colonoscopy involves taking random biopsies and sampling or removing suspicious lesions. The more samples taken, the better will be the sensitivity for detecting dysplasia because of “invisible” dysplasia by conventional colonoscopy. However, the more samples taken, the higher will be the pathology costs, the longer will be the time (and the associated costs) of the procedure, and the greater will be the morbidity of the colonoscopy. Hence, we presented data that florescence imaging of cathepsin activity correlated with dysplasia in mouse and human with inflammatory bowel disease. Cathepsins are lysosomal cysteine proteases that contribute to the proteolytic network in tumor microenvironments. The sensitivity and specificity for detecting dysplasia is 100% and 83%, respectively. This methodology presents unique advantages that may increase sensitivity and specificity of surveillance colonoscopy in patients with long-standing IBD.

    4) Transepithelial Migration of Neutrophils in Inflammatory Bowel Disease.
    The transepithelial migration (TEM) of neutrophils (PMN) is a histopathological hallmark of IBD, yet the mechanisms controlling PMN TEM remain poorly defined. The fucosylated, terminal glycan determinant Lewis X (Lex), expressed on the glycans of PMN surface glycoproteins (including MAC-1 and LFA-1), has previously been implicated in adhesive interactions between PMN and endothelium. However, little is known about the role of Lex in PMN function. Immunohistochemistry demonstrated robust expression of PMN-associated Lex within crypt abscesses in the colonic epithelium of individuals with IBD. Furthermore, engagement of Lex increased PMN adhesive interactions, both with other PMNs and with intestinal epithelial cells, blocking PMN chemotaxis and TEM. In addition to blocking PMN trafficking, targeting of Lex also altered post-migratory PMN functions, increasing both PMN phagocytosis of Salmonella enterica and release of primary granules.
    Therefore, glycans expressing the Lex determinant represent a novel target for regulating both the trafficking of PMN into the intestinal lumen and PMN function. Further, given its robust expression in migrating PMN and during inflammation, Lex may be a rational target for modulating inflammation in IBD.
  • Education And Training

  • Doctor of Philosophy in Medical Scientist, Korea University 1999
  • Doctor of Medicine, Korea University 1990
  • Full Name

  • Goo Lee